Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):

##STR00001##

or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.x are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formula (I): ##STR00001##

The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formula (I): ##STR00001##

The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided is a compound for an organic electric device, an organic electric device using the same, and an electronic device including the organic electric device. Further provided is an organic electric device having high luminous efficiency, low driving voltage, and high heat resistance can be provided, and color purity and lifespan of the organic electric device can be improved.

Provided is a compound for an organic electric device, an organic electric device using the same, and an electronic device including the organic electric device. Further provided is an organic electric device having high luminous efficiency, low driving voltage, and high heat resistance can be provided, and color purity and lifespan of the organic electric device can be improved.

Present invention is directed to Adamantane-1-carbonyl thioureas of formula I,

##STR00001##

Wherein, R is selected from 2-OH, 3-OH, 4-OH, 3,5 diCl, 4-OH, 3-CF3, 5-Br, (2-Cl, pyridine-3-yl), 3-SO2NH2, 2-Cl, 5-NO2, 2-OCH3, 3-OCH3, 4-OCH3, 3,4-diOCH3, 4-Br, 2-Br,4-CH3, 2-CH3, 4-Br, Quinolin-8-yl, 2-Br-4-isopropyl, and 3-(Dimethylamino)propane-1-yl, and their use as P2X Receptor Antagonist for the treatment of inflammation, pain, osteoporosis, neurodegenerative disorders, spinal card injury, hypertension, or urinary incontinence.

Present invention is directed to Adamantane-1-carbonyl thioureas of formula I,

##STR00001##

Wherein, R is selected from 2-OH, 3-OH, 4-OH, 3,5 diCl, 4-OH, 3-CF3, 5-Br, (2-Cl, pyridine-3-yl), 3-SO2NH2, 2-Cl, 5-NO2, 2-OCH3, 3-OCH3, 4-OCH3, 3,4-diOCH3, 4-Br, 2-Br,4-CH3, 2-CH3, 4-Br, Quinolin-8-yl, 2-Br-4-isopropyl, and 3-(Dimethylamino)propane-1-yl, and their use as P2X Receptor Antagonist for the treatment of inflammation, pain, osteoporosis, neurodegenerative disorders, spinal card injury, hypertension, or urinary incontinence.

Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naïve, G6PD-normal subjects.

##STR00001##